Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors

Eli Lilly’s VERVE-102 delivered a 62% cholesterol reduction at the highest tested dose of 1 mg/kg, with the effect sustained for up to 18 months in the Heart-2 phase 1b study. The data support Lilly’s plan to start enrolling a phase 2 trial by the end of this year, while suggesting the base editor may compete with existing PCSK9 inhibitors on efficacy and durability. The article is constructive for Lilly and Verve’s cardiovascular gene-editing platform, though patient selection and longer-term safety remain key questions.

Analysis

This is an important de-risking event for the entire in vivo cardiovascular gene-editing space: the market has been pricing these programs as binary safety stories, and a durable LDL reduction in the right efficacy band shifts the debate toward addressable patient selection rather than technical feasibility. The real commercial wedge is not broad hypercholesterolemia; it is a narrow, high-need cohort with decades of lifetime risk where one-time editing can plausibly beat adherence-driven chronic therapy. That makes the first phase 2 readout the key valuation inflection, not the current phase 1 signal.

For Amgen, the competitive threat is less about immediate share loss and more about option value erosion in the premium segment of the PCSK9 market. Chronic injectables remain advantaged in older or lower-risk patients because they are reversible, familiar, and easier to sequence with statins, but a credible durable-editing platform can siphon off the highest-value early-intervention cases and reset long-dated expectations for PCSK9 class expansion. Over time, that could compress the perceived terminal growth of the branded PCSK9 category even if near-term prescription trends remain intact.

The main risk is not efficacy decay; it is regulator- and payer-driven narrowing of the label if safety data stay “good but not pristine.” If the phase 2 population is confined to genetically defined patients and premature CAD, the opportunity may be clinically elegant but commercially modest, with adoption measured in years rather than quarters. Any whiff of off-target, liver, or irreversible safety concern would also re-open the entire platform discount for CRSP-like in vivo editing names, since investors will extrapolate from one cardiovascular program to broader editing risk appetite.

The contrarian takeaway is that the strongest upside may sit in the second-order read-through rather than the lead asset itself: this validates a delivery/safety pathway that could lower the probability of failure across other liver-directed gene-editing programs. The market may still be underestimating how quickly a successful phase 2 could force strategic deals, especially from large-cap pharma seeking durable cardiometabolic assets with differentiated dosing economics.

Key Decisions for Investors

• Short AMGN tactically into the phase 2 setup: use a 1-3 month horizon on any strength, since the market may begin discounting long-duration share loss in the premium HeFH/CAD segment; keep size modest because near-term Repatha demand is not at risk.
• Long a basket of liver-directed gene-editing/technology names versus broad biotech on a 6-12 month horizon: the cleaner safety profile here lowers platform risk premia and should support multiple expansion if phase 2 enrollment and dosing proceed without safety noise.
• Pair trade: long a cardiometabolic innovation basket / short established PCSK9 chronic therapy exposure if a higher-dose cohort is disclosed; the trade works if investors start pricing one-time therapy as the preferred option for younger, high-risk patients.
• Buy optionality on AMGN around catalyst windows only if you expect broader pipeline weakness to be overstated; otherwise avoid chasing the stock until there is clarity on whether gene editing is a niche or category-threatening solution.
• Set a trigger to add to gene-editing exposure only on confirmed phase 2 initiation and clean 3-6 month safety follow-up; if any liver signal emerges, exit quickly because the downside would be platform-wide, not asset-specific.